Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasm, Residual × Letrozole × 30 days × Clear all

Sponsor

Conditions

Breast Neoplasms 27 Ovarian Neoplasms 2 HR+/HER2- Breast Cancer 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms, Male 2 Small Cell Lung Carcinoma 1 Polycystic Ovary Syndrome 1 Neoplasms 1 Neoplasm Metastasis 1 Low Grade Serous Ovarian Cancer 1 Locoregional Recurrence 1 Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Intraductal, Noninfiltrating 1 Brain Neoplasms 1 Anatomic Stage III Breast Cancer AJCC v8 1 Anatomic Stage II Breast Cancer AJCC v8 1 Advanced Unresectable or Metastatic Breast Cancer of Adults 1 Advanced Breast Cancer 1

Interventions

blinatumomab 2 Melphalan 2 Cyclophosphamide 2 trastuzumab deruxtecan 1 tislelizumab 1 tisagenlecleucel 1 thymoglobulin 1 pembrolizumab 1 palbociclib 1 nilotinib 1 fludarabine phosphate 1 fludarabine 1 avelumab 1 Whole-Body Irradiation 1 Trastuzumab 1 Sirolimus 1 Rituximab 1 Radiotherapy 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1 Mycophenolic Acid 1 Monatide (IMS 3015) 1 Levetiracetam 1 Imatinib Mesylate 1 Hydroxychloroquine 1 Hematologic Tests 1 HMPL-013 1 Dasatinib 1 Cytarabine 1 Capecitabine 1 Busulfan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡